Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

lifirafenib (BGB-283)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BeiGene

Drug class:

EGFR inhibitor, pan-RAF inhibitor

Related drugs:

sorafenib (180)

tovorafenib (9)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

asandeutertinib (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

sorafenib (180)

tovorafenib (9)

›

BRAF V600	Melanoma	BRAF V600	Melanoma	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3
BRAF V600	Ovarian Cancer	BRAF V600	Ovarian Cancer	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3
BRAF V600	Thyroid Gland Papillary Carcinoma	BRAF V600	Thyroid Gland Papillary Carcinoma	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3
KRAS mutation	Endometrial Cancer	KRAS mutation	Endometrial Cancer	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3
BRAF V600E	Melanoma	BRAF V600E	Melanoma	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3
BRAF V600K	Melanoma	BRAF V600K	Melanoma	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3
BRAF V600E	Ovarian Cancer	BRAF V600E	Ovarian Cancer	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3
BRAF V600E	Thyroid Gland Carcinoma	BRAF V600E	Thyroid Gland Carcinoma	BGB-283 Sensitive: C4 – Case Studies BGB-283 Sensitive : C4	BGB-283 Sensitive: C4 – Case Studies BGB-283 Sensitive : C4
KRAS mutation	Solid Tumor	KRAS mutation	Solid Tumor	mirdametinib + BGB-283 Sensitive: D – Preclinical mirdametinib + BGB-283 Sensitive : D	mirdametinib + BGB-283 Sensitive: D – Preclinical mirdametinib + BGB-283 Sensitive : D
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	mirdametinib + BGB-283 Sensitive: D – Preclinical mirdametinib + BGB-283 Sensitive : D	mirdametinib + BGB-283 Sensitive: D – Preclinical mirdametinib + BGB-283 Sensitive : D
NRAS Q61	Melanoma	NRAS Q61	Melanoma	mirdametinib + BGB-283 Sensitive: D – Preclinical mirdametinib + BGB-283 Sensitive : D	mirdametinib + BGB-283 Sensitive: D – Preclinical mirdametinib + BGB-283 Sensitive : D